Microchip Signals Inventory Bottom, but Financial Risk Lingers

What happened

Microchip Technology executives have declared that the prolonged inventory correction is nearing its end, bolstered by growing design wins in data centers, aerospace, defense, and automotive markets. This optimistic claim aligns with the company's recent filing data, which shows a book-to-bill ratio of 1.06, bookings up roughly 10% quarter-over-quarter, and distributor inventory days falling from 33 to 27. However, the company's balance sheet remains strained: net debt to EBITDA stands at 4.7x, and interest coverage is a thin 0.38x, reflecting elevated leverage from the downturn. Moreover, key cost savings from the Tempe Fab 2 closure are not expected to impact the income statement until the June 2026 quarter due to FIFO inventory accounting. While stabilization is emerging, the recovery is still unproven, and the financial risk profile keeps the stock in a wait-and-see category.

Implication

The news reinforces the thesis that Microchip is in the early stages of a cyclical recovery, evidenced by improving bookings and inventory metrics. However, the company’s high net debt to EBITDA (4.7x) and low interest coverage (0.38x) leave little room for error if the recovery stalls. Cost savings from restructuring will begin to flow only in mid-2026, so near-term earnings will remain pressured. The stock’s current valuation (EV/EBITDA ~10x) is not distressed but assumes a successful turnaround; any setback in demand or margins could lead to re-levering and downside. Until leverage meaningfully deleverages and the recovery is sustained for several quarters, the prudent stance is to wait for stronger financial health before committing capital.

Thesis delta

The news provides incremental support for the stabilization thesis but does not change the overall WAIT stance. Financial leverage remains a key constraint, and the need to see sustained book-to-bill above 1.0 and a meaningful deleveraging persists. The core thesis—that Microchip is a cyclical turnaround with near-term financial risk—is unchanged.